Next Article in Journal
Molecular Dysregulation in Autism Spectrum Disorder
Previous Article in Journal
Association between Domperidone Administered via Feeding Tube and Feeding Success in Critically Ill Patients with Enteral Feeding Intolerance
Article

A Cost Decision Model Supporting Treatment Strategy Selection in BRCA1/2 Mutation Carriers in Breast Cancer

1
Departments of Mechanics Mathematics and Management, Politecnico di Bari, 70126 Bari, Italy
2
SSD Radiodiagnostica Senologica, I.R.C.C.S. Istituto Tumori “Giovanni Paolo II” di Bari, 70124 Bari, Italy
3
S.C. Chirurgia Plastica e Ricostruttiva, I.R.C.C.S. Istituto Tumori “Giovanni Paolo II” di Bari, 70124 Bari, Italy
4
SSD Diagnostica Molecolare e Farmacogenetica, I.R.C.C.S. Istituto Tumori “Giovanni Paolo II” di Bari, 70124 Bari, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Matthias Schwab
J. Pers. Med. 2021, 11(9), 847; https://doi.org/10.3390/jpm11090847
Received: 15 July 2021 / Revised: 21 August 2021 / Accepted: 25 August 2021 / Published: 27 August 2021
In this paper, a cost decision-making model that compares the healthcare costs for diverse treatment strategies is built for BRCA-mutated women with breast cancer. Moreover, this model calculates the cancer treatment costs that could potentially be prevented, if the treatment strategy with the lowest total cost, along the entire lifetime of the patient, is chosen for high-risk women with breast cancer. The benchmark of the healthcare costs for diverse treatment strategies is selected in the presence of uncertainty, i.e., considering, throughout the lifetime of the patient, the risks and complications that may arise in each strategy and, therefore, the costs associated with the management of such events. Our results reveal a clear economic advantage of adopting the cost decision-making model for benchmarking the healthcare costs for various treatment strategies for BRCA-mutated women with breast cancer. The cost savings were higher when all breast cancer patients underwent counseling and genetic testing before deciding on any diagnostic-therapeutic path, with a probability of obtaining savings of over 75%. View Full-Text
Keywords: breast cancer; BRCA-carriers management; cost decision model; economic evaluation; uncertainty breast cancer; BRCA-carriers management; cost decision model; economic evaluation; uncertainty
Show Figures

Figure 1

MDPI and ACS Style

Carbonara, N.; La Forgia, D.; Pellegrino, R.; Ressa, C.; Tommasi, S. A Cost Decision Model Supporting Treatment Strategy Selection in BRCA1/2 Mutation Carriers in Breast Cancer. J. Pers. Med. 2021, 11, 847. https://doi.org/10.3390/jpm11090847

AMA Style

Carbonara N, La Forgia D, Pellegrino R, Ressa C, Tommasi S. A Cost Decision Model Supporting Treatment Strategy Selection in BRCA1/2 Mutation Carriers in Breast Cancer. Journal of Personalized Medicine. 2021; 11(9):847. https://doi.org/10.3390/jpm11090847

Chicago/Turabian Style

Carbonara, Nunzia, Daniele La Forgia, Roberta Pellegrino, Cosmo Ressa, and Stefania Tommasi. 2021. "A Cost Decision Model Supporting Treatment Strategy Selection in BRCA1/2 Mutation Carriers in Breast Cancer" Journal of Personalized Medicine 11, no. 9: 847. https://doi.org/10.3390/jpm11090847

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop